Novartis (Switzerland) Today
| NOVN Stock | CHF 91.56 0.57 0.63% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Novartis is selling for under 91.56 as of the 21st of November 2024; that is 0.63 percent increase since the beginning of the trading day. The stock's lowest day price was 90.74. Novartis has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Novartis AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS N operates under Drug ManufacturersGeneral classification in Switzerland and is traded on Switzerland Exchange. The company has 2.12 B outstanding shares. More on Novartis AG
Moving together with Novartis Stock
| 0.74 | ROG | Roche Holding AG | PairCorr |
| 0.71 | RO | Roche Holding AG | PairCorr |
| 0.68 | SNBN | Schweizerische Nationalbank | PairCorr |
Moving against Novartis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novartis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novartis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novartis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Novartis AG (NOVN) is traded on SIX Swiss Exchange in Switzerland and employs 102,000 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 170.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novartis AG operates under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.12 B outstanding shares.
Novartis AG has accumulated about 4.64 B in cash with 14.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.0.
Check Novartis Probability Of Bankruptcy
Ownership AllocationNovartis AG maintains a total of 2.12 Billion outstanding shares. 30% of Novartis outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novartis Ownership Details
Novartis AG Risk Profiles
Although Novartis' alpha and beta are two of the key measurements used to evaluate Novartis' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.6423 | |||
| Standard Deviation | 0.9152 | |||
| Variance | 0.8375 | |||
| Risk Adjusted Performance | (0.12) |
Novartis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Novartis Corporate Management
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor | Chief Sandoz | Profile | |
| Steffen Lang | Pres Operations | Profile | |
| MarieFrance Tschudin | Pres Officer | Profile | |
| Paul Penepent | Head Accounting | Profile | |
| Samir MD | Global Relations | Profile | |
| Robert PharmD | Chief Officer | Profile | |
| Klaus Moosmayer | Risk Ethics | Profile |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.